Completed PHASE3 INTERVENTIONAL 2-arm NCT02839473

Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial (HYDROSORB)

Hydrosorb® Versus Control (Water Based Spray) in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial

Sponsor: Institut Curie

Conditions Breast Cancer Radiation Dermatitis

Interventions Castalie water spray Hydrogel Hydrosorb®

Updated 8 times since 2017 Last updated: Sep 15, 2025 Started: Mar 31, 2010 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and Radiation Dermatitis and is currently completed. Institut Curie leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2024 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Feb 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Curie
Paul Hartmann

Data source: Institut Curie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France
• Saint-Cloud, France